



SARS-CoV-2 Variants: Unraveling Vaccines and Immune Responses

Guest Editor:

Dr. Zijun Wang

Laboratory of Molecular
Immunology, The Rockefeller
University, New York City, NY, USA

Deadline for manuscript
submissions:

closed (31 March 2024)

Message from the Guest Editor

This Special Issue explores the relationship between SARS-CoV-2 variants, vaccine development, and the immune system. We encourage submissions on genomic, molecular, and structural features of SARS-CoV-2 variants and their implications for vaccine effectiveness. We also seek studies on immune response dynamics in the context of these variants. Potential topics of interest include, but are not limited to: 1. Comprehensive characterization of emerging SARS-CoV-2 variants and their unique features; 2. Evaluation of the effectiveness of currently available vaccines against variant strains; 3. Analysis of the immune response elicited by vaccines targeting SARS-CoV-2 variants; 4. Investigation of variant-specific immune evasion mechanisms and their impact on breakthrough infections; 5. Long-term durability and persistence of vaccine-induced immunity against variant strains; 6. Assessment of alternative vaccination strategies or booster doses to address variant challenges; 7. Understanding the implications of SARS-CoV-2 variants on global vaccination efforts and public health interventions; 8. Real-world effectiveness studies of vaccines against variant strains in diverse populations.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com